Latest & greatest articles for adverse events

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adverse events or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adverse events and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adverse events

361. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use

Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use Tramer M R, Moore R A, Reynolds D J, McQuay H J Authors' objectives To estimate the incidence of death from (...) Research Student Award; Swiss National Research Foundation, grant number 3233-51939.97; European Union Biomed 2, grant number BMH14 CT95 0172; NHS Research and Development Health Technology Assessment Programme, grant number 94/11/4; Pain Research Fund. Bibliographic details Tramer M R, Moore R A, Reynolds D J, McQuay H J. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 2000; 85(1-2): 169-182 PubMedID Other

2000 DARE.

362. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. (PubMed)

Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. Pharmacist review of medication orders in the intensive care unit (ICU) has been shown to prevent errors, and pharmacist consultation has reduced drug costs. However, whether pharmacist participation in the ICU at the time of drug prescribing reduces adverse events has not been studied.To measure the effect of pharmacist participation on medical rounds in the ICU on the rate of preventable adverse (...) drug events (ADEs) caused by ordering errors.Before-after comparison between phase 1 (baseline) and phase 2 (after intervention implemented) and phase 2 comparison with a control unit that did not receive the intervention.A medical ICU (study unit) and a coronary care unit (control unit) in a large urban teaching hospital.Seventy-five patients randomly selected from each of 3 groups: all admissions to the study unit from February 1, 1993, through July 31, 1993 (baseline) and all admissions

1999 JAMA

363. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat

Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat Tfelt-Hansen P Authors (...) ' objectives To assess the efficacy, speed of onset and adverse events of sumatriptan given using various routes of administration for migraine treatment. Searching The author searched MEDLINE (over the entire date range, performed in April 1997), using the terms 'migraine', 'sumatriptan', and 'clinical trials'. Printouts from the database on clinical trials on sumatriptan were obtained from Glaxo Wellcome Denmark. The journals 'Archives of Neurology', 'Neurology', 'Headache' and 'Cepalalgia' from 1990

1998 DARE.

364. Risk of serious adverse events in hypertensive patients receiving isradipine: a meta-analysis

Risk of serious adverse events in hypertensive patients receiving isradipine: a meta-analysis Risk of serious adverse events in hypertensive patients receiving isradipine: a meta-analysis Risk of serious adverse events in hypertensive patients receiving isradipine: a meta-analysis Ross S D, Kupelnick B, Kumashiro M, Arellano F M, Mohanty N, Allen I E Authors' objectives The overall objective was to assess the risk of serious events associated with the use of any formulation of isradipine (...) as monotherapy in hypertension. The specific questions were: 1) Are the major adverse event rates higher with isradipine or isradipine sustained-release than with placebo or active controls? 2) Are the rates of withdrawal due to major adverse events higher with isradipine/isradipine sustained-release than with placebo or active controls? 3) What is the association of isradipine formulations with major adverse events? 4) Are the major adverse event rates from the sponsor's unpublished trials similar

1997 DARE.

365. Placebo-controlled trial of two acellular pertussis vaccines in Sweden--protective efficacy and adverse events. Ad Hoc Group for the Study of Pertussis Vaccines. (PubMed)

Placebo-controlled trial of two acellular pertussis vaccines in Sweden--protective efficacy and adverse events. Ad Hoc Group for the Study of Pertussis Vaccines. 3801 children aged 5-11 months were entered into a blind placebo-controlled trial of pertussis vaccine. 954 were randomised to receive placebo (vaccine solvent), 1419 to receive a two-component vaccine containing formaldehyde detoxified lymphocytosis promoting factor (LPF) and filamentous haemagglutinin, and 1428 to receive an LPF

1988 Lancet